Regulation of cancer cell migration and bone metastasis by RANKL.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Bone metastases are a frequent complication of many cancers that result in severe disease burden and pain. Since the late nineteenth century, it has been thought that the microenvironment of the local host tissue actively participates in the propensity of certain cancers to metastasize to specific organs, and that bone provides an especially fertile 'soil'. In the case of breast cancers, the local chemokine milieu is now emerging as an explanation for why these tumours preferentially metastasize to certain organs. However, as the inhibition of chemokine receptors in vivo only partially blocks metastatic behaviour, other factors must exist that regulate the preferential metastasis of breast cancer cells. Here we show that the cytokine RANKL (receptor activator of NF-kappaB ligand) triggers migration of human epithelial cancer cells and melanoma cells that express the receptor RANK. RANK is expressed on cancer cell lines and breast cancer cells in patients. In a mouse model of melanoma metastasis, in vivo neutralization of RANKL by osteoprotegerin results in complete protection from paralysis and a marked reduction in tumour burden in bones but not in other organs. Our data show that local differentiation factors such as RANKL have an important role in cell migration and the tissue-specific metastatic behaviour of cancer cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MDA-231 cells and other human breast cancer cells have been shown to express RANK (101, 336)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [336]
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationInvolvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Bone Resorption by Osteoclasts
Teitelbaum, S. L. (2000) · Science · doi:10.1126/science.289.5484.1504 · Cited by 3,962
Dissemination and growth of cancer cells in metastatic sites
Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc865 · Cited by 3,911
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Self-citationMetastasis to bone: causes, consequences and therapeutic opportunities
Mundy, G. R. (2002) · Nature Reviews Cancer · doi:10.1038/nrc867 · Cited by 2,777
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,310
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Fata, J. E., Kong, Y.-Y., Li, J., Sasaki, T., Irie-Sasaki, J., Moorehead, R. A., Elliott, R., Scully, S., Voura, E. B., Lacey, D. L., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00103-3 · Cited by 756
Self-citation
Cited by
Items 201–300 of 864
Beristain, A. G., Narala, S., Grappa, M. A. D., & Khokha, R. (2012) · Journal of Cell Science · doi:10.1242/jcs.094029 · Cited by 69
“There has been increasing attention assigned to the role of RANKL in regulating cell motility (Jones et al., 2006; Mori et al., 2007; Armstrong et al., 2008; Chen et al., 2010; Hsu et al., 2010; Sabbota et al., 2010) and metastasis (Jones et al.”
BackgroundSelf-citationDouni, E. K., Rinotas, V. E., Makrinou, E., Zwerina, J., Penninger, J. M., Eliopoulos, E., Schett, G. A., & Kollias, G. A. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr510 · Cited by 69
“Although RANKL is best known for its role in bone resorption, it also plays multiple roles in the immune system (4,5,13,18,19), in mammary gland development during pregnancy (20), thermoregulation (21), cancer metastasis (22) and hormone-derived breast development (23).”
BackgroundSelf-citationOwen, S., Ye, L., Sanders, A. J., Mason, M. D., & Jiang, W. G. (2013) · PubMed · Cited by 68
Xu, S., Zhou, W., Ge, J., & Zhang, Z. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8415 · Cited by 68
PAUF functions in the metastasis of human pancreatic cancer cells and upregulates CXCR4 expression
Lee, Y., Kim, S.-H., Park, H., Park, E. H., Huang, S. M., Jeon, S. B., Kim, J.-M., Lim, D.-S., & Koh, S. S. (2009) · Oncogene · doi:10.1038/onc.2009.298 · Cited by 67
Bone metastases: When and how lung cancer interacts with bone
Roato, I. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i2.149 · Cited by 66
Role of the RANK/RANKL pathway in breast cancer
Kiesel, L., & Kohl, A. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.01.001 · Cited by 64
RANKL/RANK – From bone physiology to breast cancer
Sigl, V., & Penninger, J. M. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.01.002 · Cited by 63
Self-citationProgesterone regulation of stem and progenitor cells in normal and malignant breast
Axlund, S. D., & Sartorius, C. A. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.021 · Cited by 63
RANK ligand inhibition with denosumab for the management of osteoporosis
Lewiecki, E. M. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.10.1041 · Cited by 63
“The observations that RANK is expressed by epithelial tumour cells and that RANKL stimulates tumour cell migration to bone [66] suggest that RANKL inhibition with drugs such as denosumab may be useful for the prevention and treatment of bone metastases.”
BackgroundRANK as a therapeutic target in cancer
González‐Suárez, E., & Sanz‐Moreno, A. (2016) · FEBS Journal · doi:10.1111/febs.13645 · Cited by 63
A T Cell View of the Bone Marrow
Bonomo, A. C., Monteiro, A. C., Gonçalves-Silva, T., Cordeiro-Spinetti, E., Galvani, R. G. A., & Balduíno, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00184 · Cited by 63
“Regulation of tumor cell migration to the bone as well as primary mammary tumor growth had also been reported and relate to physiological activities of these molecules (126).”
BackgroundBiochemical markers in oncology. Part I: Molecular basis. Part II: Clinical uses
Voorzanger‐Rousselot, N., & Garnero, P. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.01.008 · Cited by 63
Breast cancer bone metastasis and current small therapeutics
Cicek, M., & Oursler, M. J. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9035-x · Cited by 63
“[21] has found that RANKL can stimulate migration of epithelial cancer cells that express RANK.”
BackgroundDenosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
Raje, N. S., & Yee (2012) · Clinical Interventions in Aging · doi:10.2147/cia.s14566 · Cited by 62
“The motivation for this study is based on animal models suggesting that RANKL-RANK signaling plays an important role in breast cancer tumorigenesis(35) and in metastasis (in melanoma mouse models).(36) These preclinical findings suggest that inhibition of RANKL via denosumab, in addition to minimizing bone loss, may p…”
MethodRANK expression on breast cancer cells promotes skeletal metastasis
Blake, M., Tometsko, M. E., Miller, R. E., Jones, J. C., & Dougall, W. C. (2013) · Clinical & Experimental Metastasis · doi:10.1007/s10585-013-9624-3 · Cited by 62
Yonemori, K., Fujiwara, Y., Minami, H., Kitagawa, K., Fujii, H., Arai, T., Sohn, W. Y., Ohkura, M., & Ohtsu, T. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00803.x · Cited by 62
Chen, G., Luo, Y., Eriksson, D., Meng, X., Cheng, Q., Bäuerle, T., Chen, X., Schett, G. A., & Bözec, A. (2016) · Oncotarget · doi:10.18632/oncotarget.8474 · Cited by 62
“To improve the prognosis of metastatic melanoma, interventions could be required, which target both the disseminating seed and the metastatic soil (or niche) [11, 15].”
Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis
Li, X.-M., Liu, Y., Wu, B., Dong, Z., WANG, Y., Lu, J., SHI, P., Bai, W., & Wang, Z. (2014) · Oncology Reports · doi:10.3892/or.2014.3511 · Cited by 61
Son, J., Lee, J.-H., Kim, H., Ha, H., & Lee, Z. H. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.06.087 · Cited by 61
“Apart from chemotactic potential, RANKL/RANK signaling is highly connected to breast cancer bone metastasis through a vicious cycle of bone destruction and cancer growth [1].”
BackgroundInfluentialC-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathway
Zhang, L., Teng, Y., Zhang, Y., LIU, J., Xu, L., Qu, J., Hou, K., Yang, X., Liu, Y., & Qu, X. (2011) · Oncology Letters · doi:10.3892/ol.2011.487 · Cited by 61
“Previous studies regarding RANKL/RANK signal pathways have mainly focused on melanoma, lung and prostate cancer cells (4,13,14).”
InfluentialGenes associate with abnormal bone cell activity in bone metastasis
Roodman, G. D. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9372-x · Cited by 61
Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer
Kiechl, S. J., Schramek, D., Widschwendter, M., Fourkala, E.-O., Zaikin, A. A., Jones, A., Jaeger, B. A., Rack, B. K., Janni, W. J., Scholz, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14013 · Cited by 61
“RANKL is expressed in primary breast cancers in patients and human breast cancer cells lines [14-19, 23] and, in mouse studies, the RANKL/RANK system is an important molecular link between progestins and oncogene-driven epithelial carcinogenesis [12, 13].”
BackgroundSelf-citationMa, Y. V., Lam, C., Dalmia, S., Gao, P., Young, J., Middleton, K., Liu, C., Xu, H., & You, L. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26745 · Cited by 61
Mechanisms of Organ-Specific Metastasis of Breast Cancer
Nolan, E., Kang, Y., & Malanchi, I. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041326 · Cited by 60
The Cellular Dynamics of Bone Remodeling: A Mathematical Model
Ryser, M. D., Komarova, S. V., & Nigam, N. (2010) · SIAM Journal on Applied Mathematics · doi:10.1137/090746094 · Cited by 63
Self-citationGuise, T. A. (2009) · Genes & Development · doi:10.1101/gad.1854909 · Cited by 60
“In addition to enhancing bone resorption in response to cancer cell signals, RANKL, RANK, and OPG may also play a role in cancer cell proliferation, and migration to and invasion of bone (Jones et al. 2006).”
Chang, Y.-T., Lin, T.-P., Campbell, M., Pan, C., Lee, S.-H., Lee, H., Yang, M., Kung, H.-J., & Chang, P. (2017) · Scientific Reports · doi:10.1038/srep42795 · Cited by 60
Bartelt, A., Behler-Janbeck, F., Beil, F. T., Koehne, T., Müller, B., Schmidt, T., Heine, M., Ochs, L., Yılmaz, T., Dietrich, M. F., et al. (2018) · Bone Research · doi:10.1038/s41413-017-0006-3 · Cited by 60
RANKL/RANK/OPG: Key Therapeutic Target in Bone Oncology
Ando, K., Mori, K., Rédiní, F., & Heymann, D. (2008) · Current Drug Discovery Technologies · doi:10.2174/157016308785739857 · Cited by 60
Talukdar, S., & Kundu, S. C. (2013) · Advanced Functional Materials · doi:10.1002/adfm.201300312 · Cited by 55
Criscitiello, C., Viale, G., Gelao, L., Espósito, A., Laurentiis, M. D., Placido, S. D., Santangelo, M. L., Goldhirsch, A., & Curigliano, G. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.001 · Cited by 59
“Moreover it has recently been reported that RANKL is a chemotactic factor for osteoclasts and for RANK-expressing tumor cells, thus facilitating metastatization [32].”
BackgroundTallarico, M., Canullo, L., Xhanari, E., & Meloni, S. M. (2015) · Clinical Oral Implants Research · doi:10.1111/clr.12662 · Cited by 58
“The resulting inhibition of normal bone resorption leads to reduced bone turnover, increased bone density, improved mineralization and reduced risk of fracture (Jones et al. 2006).”
BackgroundBone marrow endothelium-targeted therapeutics for metastatic breast cancer
Mai, J., Huang, Y., Mu, C., Zhang, G., Xu, R., Guo, X., Xia, X., Volk, D. E., Lokesh, G. L.-R., Thiviyanathan, V., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.057 · Cited by 58
“Although several bisphosphonates [6] and a neutralizing antibody targeting RANKL [7,8] have shown promising results on management of tumor progression, benefits on improved survival was observed in only a small population of patients [9,10]. d therapeutics for metastatic breast cancer, J. Control.”
Angela, Y., Haferkamp, S., Weishaupt, C., Ugurel, S., Becker, J. C., Oberndörfer, F., Alar, V., Satzger, I., & Gutzmer, R. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02353-5 · Cited by 58
The Roadmap of RANKL/RANK Pathway in Cancer
Casimiro, S., Vilhais, G., Gomes, I., & Costa, L. (2021) · Cells · doi:10.3390/cells10081978 · Cited by 58
“In vitro, RANKL expressed by LNCaP cells was shown to be osteoclastogenic [48].”
BackgroundInfluentialNF-κB signaling in therapy resistance of breast cancer: Mechanisms, approaches, and challenges
Guo, Q. H., Jin, Y., Lin, M., Zeng, C., & Zhang, J. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122684 · Cited by 57
Jin, H., Yu, Y., Hu, Y., Lu, C., Li, J., Gu, J., Zhang, L., Huang, H., Zhang, D., Wu, X., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2680 · Cited by 57
“com/oncotarget regulation of reactive oxygen species [11], is also thought to be closely associated with bladder cancer invasion and metastasis.”
BackgroundThe RANKL/RANK system as a therapeutic target for bone invasion by oral squamous cell carcinoma
Jimi, E., Shin, M., FURUTA, H., Tada, Y., & Kusukawa, J. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1794 · Cited by 57
Ibrahim, T., Sacanna, E., Gaudio, M., Mercatali, L., Scarpi, E., Zoli, W., Serra, P., Ricci, R., Serra, L., Kang, Y., et al. (2011) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.05.001 · Cited by 57
Classical and Non-Classical Progesterone Signaling in Breast Cancers
Pedroza, D. A., Subramani, R., & Lakshmanaswamy, R. (2020) · Cancers · doi:10.3390/cancers12092440 · Cited by 57
“RANK, the receptor for RANKL, has also been demonstrated to be expressed in breast cancer cells and plays a fundamental role in the proliferation, differentiation and migration of these cells [86].”
Backgroundde Castro, J., García, R., Garrido, P., Isla, D., Massutí, B., Blanca, B., & Vázquez, J. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.06.004 · Cited by 56
Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone
Hirbe, A. C., Rubin, J., Uluçkan, Ö., Morgan, E. A., Eagleton, M. C., Prior, J. L., Piwnica-Worms, D. R., & Weilbaecher, K. N. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705203104 · Cited by 56
Phytochemicals potently inhibit migration of metastatic breast cancer cells
Ham, S. L., Nasrollahi, S., Shah, K. N., Soltisz, A. M., Paruchuri, S. M., Yun, Y., Luker, G. D., Bishayee, A., & Tavana, H. (2015) · Integrative Biology · doi:10.1039/c5ib00121h · Cited by 56
Immune system and bone microenvironment: rationale for targeted cancer therapies
Gnoni, A., Brunetti, O., Vito, L., Calabrese, A., Antonel-la, A., Calbi, R., Solimando, A. G., & Licchetta, A. (2020) · Oncotarget · doi:10.18632/oncotarget.27439 · Cited by 55
Skeletal and extraskeletal actions of denosumab
Sinningen, K., Tsourdi, E. A., Rauner, M., Rachner, T. D., Hamann, C., & Hofbauer, L. C. (2012) · Endocrine · doi:10.1007/s12020-012-9696-x · Cited by 55
Smith, G. A., Howell, G. J., Phillips, C., Muench, S. P., Ponnambalam, S., & Harrison, M. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.723395 · Cited by 54
“0 (56) (64) a Data are from an initial pH of 7.”
BackgroundCathepsin K: A Versatile Potential Biomarker and Therapeutic Target for Various Cancers
Qian, D., He, L., Zhang, Q., Li, W., Tang, D., Wu, C., Yang, F., Li, K., & Zhang, H. (2022) · Current Oncology · doi:10.3390/curroncol29080471 · Cited by 54
“RANKL induces the migration of MDA-MB-231, Hs578T and MCF7 breast cancer cells [52].”
BackgroundHo, P. W. M., Goradia, A., Russell, M. R., Chalk, A. M., Milley, K. M., Baker, E. K., Danks, J. A., Slavin, J. L., Walia, M., Crimeen‐Irwin, B., et al. (2014) · Oncogene · doi:10.1038/onc.2014.217 · Cited by 53
Hypoxia induces RANK and RANKL expression by activating HIF-1α in breast cancer cells
Tang, Z.-N., Zhang, F., Tang, P., Qi, X., & Jiang, J. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.04.035 · Cited by 52
“It has been demonstrated that RANKL can promote the motility of breast cancer cells expressing the RANK receptor [6].”
BackgroundInfluentialLamoureux, F., Picarda, G., Rousseau, J., Gourden, C., Battaglia, S., Charrier, C., Pitard, B., Heymann, D., & Rédini, F. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0497 · Cited by 48
“shown that RANKL is implicated in the pathogenesis of bone metastasis at several levels: increased bone resorption as a result of excess RANKL results in the release of growth factors that facilitate tumor cell division and survival, and a recent study suggested a role for RANKL as a chemoattractant for certain cancer…”
BackgroundNew therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment
Cheung, L. C., Tickner, J. C., Hughes, A. M., Skut, P., Howlett, M., Foley, B. A., Oommen, J., Wells, J. E., He, B., Singh, S., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0144-7 · Cited by 52
“Tumor invasion into bone is associated with RANKL-mediated osteoclastogenesis [63].”
BackgroundRachner, T. D., Kasimir‐Bauer, S., Göbel, A., Erdmann, K., Hoffmann, O., Browne, A., Wimberger, P., Rauner, M., Hofbauer, L. C., Kimmig, R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2482 · Cited by 52
“RANKL is a mediator of progestin-driven breast carcinogenesis (13, 14) and also promotes the migration of highly osteolytic breast and melanoma cells in preclinical models of bone metastases (15).”
BackgroundOsteoclast precursors acquire sensitivity to breast cancer derived factors early in differentiation
Guo, Y., Tiedemann, K., Khalil, J. A., Russo, C., Siegel, P. M., & Komarova, S. V. (2008) · Bone · doi:10.1016/j.bone.2008.03.026 · Cited by 52
Self-citationMartinez, L. M., Vallone, V. B. F., Labovsky, V., Choi, H., Hofer, E. L., Feldman, L. J., Bordenave, R. H., Batagelj, E., Dimase, F., Villafañe, A. R., et al. (2013) · Clinical & Experimental Metastasis · doi:10.1007/s10585-013-9622-5 · Cited by 51
“Moreover, both RANKL and the same MIF stimulate the in vitro migration of preosteoclasts across bone endothelial cells [11].”
BackgroundTargeting RANKL in breast cancer: bone metastasis and beyond
Azim, H. A., & Azim, H. A. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.177 · Cited by 51
Zheng, Y., Chow, S., Börnert, K., Basel, D., Mikuscheva, A., Kim, S., Fong-Yee, C., Trivedi, T., Buttgereit, F., Sutherland, R. L., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2231 · Cited by 51
“Finally, human recombinant RANKL induces migration of RANK‐expressing breast cancer andmelanoma cells in vitro.((26)) These data suggest a role of RANKL and RANK in bone metastasis.”
BackgroundInfluentialTargeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone
Zheng, Y., Basel, D., Chow, S.-O., Fong-Yee, C., Kim, S., Buttgereit, F., Dunstan, C., Zhou, H., & Seibel, M. (2014) · Clinical and Experimental Metastasis · doi:10.1007/s10585-014-9680-3 · Cited by 45
CCL20 mediates RANK/RANKL-induced epithelial-mesenchymal transition in endometrial cancer cells
Liu, Y., Wang, J., Ni, T., Wang, L., Wang, Y., & Sun, X. G. (2016) · Oncotarget · doi:10.18632/oncotarget.8291 · Cited by 50
Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis
Chen, J., Zhou, L., Liu, X., Wen, X., Li, H., & Li, W. (2020) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-020-01105-1 · Cited by 50
The Role of Inflammation in Breast and Prostate Cancer Metastasis to Bone
Göbel, A., Dell'Endice, S., Jaschke, N., Pählig, S., Shahid, A., Hofbauer, L. C., & Rachner, T. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105078 · Cited by 50
“Neutralization of RANKL/RANK signaling by OPG prevents intraosseous tumor burden in mouse models [80].”
BackgroundOsteoprotegerin in Bone Metastases: Mathematical Solution to the Puzzle
Ryser, M. D., Qu, Y., & Komarova, S. V. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002703 · Cited by 50
“Although the RANK-RANKL dynamics are known to play an important role in bone metastases [16,39], there is uncertainty regarding the actual source of RANKL.”
InfluentialSelf-citationCCN5/WISP-2: A micromanager of breast cancer progression
Banerjee, S. K., & Banerjee, S. (2012) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-012-0158-2 · Cited by 49
“, Snail, Twist, p53, RANKL, CXCR4 and ligands) and their molecular cross talks have been reported to trigger EMT followed by invasive changes (Muller et al. 2001; Kang and Massague 2004; Thiery and Sleeman 2006; Jones et al. 2006; Aylon and Oren 2007; Oren and Bartek 2007; Weisz et al. 2007).”
BackgroundRegulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment
Lamoureux, F., Moriceau, G., Picarda, G. G. A., Rousseau, J., Trichet, V., & Rédiní, F. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.08.004 · Cited by 49
From the ranks of mammary progesterone mediators, RANKL takes the spotlight
Fernandez‐Valdivia, R., & Lydon, J. P. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.030 · Cited by 47
“However, an obvious question arising from the murine mammary tumor studies is: Does progesterone (or progestins) use the same molecular mediators in both mammary morphogenesis and tumorigenesis? In the case of RANKL, the question is particularly pertinent when considering this cytokine's unique importance in progester…”
BackgroundMouritzen, M. T., Carus, A., Ladekarl, M. B., Meldgaard, P., Nielsen, A. W. M., Livbjerg, A., Larsen, J. W., Skúladóttir, H., Kristiansen, C., Wedervang, K., et al. (2021) · Cancers · doi:10.3390/cancers13194846 · Cited by 47
“However, this information is essential because the immune and skeletal systems are closely linked; for example, the receptor activator of nuclear factor-κB ligand (RANKL) stimulation suppresses T-cell killing and enhances immunosuppression in the bone tumor microenvironment [30,31].”
BackgroundA convenient clinically relevant model of human breast cancer bone metastasis
Garcia, T., Jackson, A. M., Bachelier, R., Clément-Lacroix, P., Baron, R., Clézardin, P., & Pujuguet, P. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9099-1 · Cited by 47
“This axis is perturbed in bone metastases since breast cancer cells express Rank [31].”
BackgroundInfluentialWang, Z., Andrade, N., Torp, M., Wattananit, S., Arvidsson, A., Kokaia, Z., Jørgensen, J. R., & Lindvall, O. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.156 · Cited by 47
Rousseau, J., Escriou, V., Lamoureux, F., Brion, R., Chesneau, J., Battaglia, S., Amiaud, J., Scherman, D., Heymann, D., Rédini, F., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.455 · Cited by 40
“(16) Specific neutralization of RANKL has been achieved by either soluble RANK-IgG-Fc,(17) recombinant OPG,(18) or OPG-like peptidomimetic administrations(19) in various preclinical models of osteolytic diseases and in osteosarcoma models.”
MethodYang, H., Wang, R., Zeng, F., Zhao, J. V., Peng, S., Ma, Y., Chen, S., Ding, S., Zhong, L., Guo, W., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11948 · Cited by 46
“There was evidence that the ability of breast cancer cells to activate osteo‐ clasts is similar to that of normal glandular tissue of mammary epithelial cells during lactation; therefore, breast cancer cells have intrinsic properties that allow them to metastasize to bone tissue (26).”
Physiology and pathophysiology of the RANKL/RANK system
Hanada, R., Hanada, T., & Penninger, J. M. (2010) · Biological Chemistry · doi:10.1515/bc.2010.149 · Cited by 46
Self-citationNovel Bone-Targeted Strategies in Oncology
Vallet, S., Smith, M. R., & Raje, N. S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0600 · Cited by 46
Effects of Isoform-selective Phosphatidylinositol 3-Kinase Inhibitors on Osteoclasts
Shugg, R. P. P., Thomson, A., Tanabe, N., Kashishian, A., Steiner, B. H., Puri, K. D., Pereverzev, A., Lannutti, B. J., Jirik, F. R., Dixon, S. J., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.507525 · Cited by 45
Self-citationVargas, G., Bouchet, M., Bouazza, L., Reboul, P., Boyault, C., Gervais, M., Kan, C. W. S., Benetollo, C., Brevet, M., Croset, M., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0579-3 · Cited by 45
“mechanism has been observed not only in BCa but also in other cancers [29] indicating that RANKL is one of the important “soil” factors that promote BCa-Rank+cell bone”
BackgroundOsteoimmunology: A View from the Bone
David, J. (2007) · Advances in immunology · doi:10.1016/s0065-2776(07)95005-1 · Cited by 45
Kawano, Y., Diez, S., Onganer, P. U., Darrington, R. S., Waxman, J. H., & Kypta, R. M. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604976 · Cited by 45
“A more recent report indicates that many cancer cells (including the prostate cancer line LNCaP) express RANK and respond to RANKL (Jones et al, 2006).”
BackgroundPapanastasiou, A. D., Sirinian, C., & Kalofonos, H. P. (2012) · Breast Cancer Research · doi:10.1186/bcr3234 · Cited by 45
“MDA-MB-231 is reported to be a RANKL-responsive breast cancer cell line [11] and as such we examined cell viability after RANKL treatment.”
BackgroundInhibition of the classical NF-κB pathway prevents osteoclast bone-resorbing activity
Soysa, N. S., Alles, N., Shimokawa, H., Jimi, E., Aoki, K., & Ohya, K. (2009) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-008-0026-6 · Cited by 45
“that induces actin ring formation [22, 23] and osteoclast migration [ 24 ].”
BackgroundSubik, K., Shu, L., Wu, C., Liang, Q., Hicks, D. G., Boyce, B. F., Schiffhauer, L. M., Chen, D., Chen, C., Tang, P., et al. (2012) · Bone · doi:10.1016/j.bone.2011.12.022 · Cited by 44
“For example, in osteoblast-like cell lines, WWP1 promoted degradation of Runx2 through the adaptor protein Schnurri-3 [24], and Runx2 expression is positively associated with breast and prostate cancer bone metastasis [25,26].”
BackgroundMayzlish‐Gati, E., Laufer, D., Grivas, C., Shaknof, J., Sananes, A., Bier, A., Ben-Harosh, S., Belausov, E., Johnson, M. D., Artuso, E., et al. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1070982 · Cited by 44
The RANK–RANKL axis: an opportunity for drug repurposing in cancer?
Peters, S., Clézardin, P., Márquez‐Rodas, I., Niepel, D., & Gedye, C. A. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-018-02023-5 · Cited by 44
Obesity, Inflammation, and Advanced Prostate Cancer
Rodríguez-Olivas, A. O., & Price, R. S. (2020) · Nutrition and Cancer · doi:10.1080/01635581.2020.1856889 · Cited by 44
RANKL Blockade Reduces Cachexia and Bone Loss Induced by Non-Metastatic Ovarian Cancer in Mice
Pin, F., Jones, A. J., Huot, J. R., Narasimhan, A., Zimmers, T. A., Bonewald, L. F., & Bonetto, A. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4480 · Cited by 44
“RANKL expression was shown to be elevated in many solid tumors, including breast, prostate, liver, gastric, and ovarian,((18-21)) and was described to correlate with poor clinical outcomes in patients affected with ovarian tumors.”
BackgroundBone metastasis in breast cancer: The story of RANK-Ligand
Azim, H. A., Kamal, N. S., & Azim, H. A. (2012) · Journal of the Egyptian National Cancer Institute · doi:10.1016/j.jnci.2012.06.002 · Cited by 44
“As mentioned earlier, human breast cancer cell lines and tissue specimens are reported to express RANK protein on their surface and it has been suggested that RANKL may act as a chemotactic factor for these cancer cells [18].”
BackgroundStopeck, A., & Brown-Glaberman, U. A. (2012) · Biologics · doi:10.2147/btt.s20677 · Cited by 43
“There are data to suggest that RANKL may also be integral to the spread and propagation of cancer cells in bone.(45) The Phase III D-CARE trial is underway to assess the effect of denosumab on disease recurrence in patients with stage II and III high-risk, early-stage breast cancer.”
C-Met/miR-130b axis as novel mechanism and biomarker for castration resistance state acquisition
Cannistraci, A., Federici, G., Addario, A., Pace, A. L. D., Grassi, L., Muto, G., Collura, D., Signore, M., Salvo, L. D., Sentinelli, S., et al. (2017) · Oncogene · doi:10.1038/onc.2016.505 · Cited by 43
Xing, L., Zhang, M., & Chen, D. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22586 · Cited by 43
“Shn3 / mice develop severe osteosclerosis with dramatically increased bone mass. Shn3 enhances Runx2 protein ubiquitination and degradation through recruitment of WWP1 to Runx2 in vitro, leading to a hypothesis that WWP1 mediates osteosclerotic phenotype of Shn3 / mice [Jones et al., 2006, 2007].”
BackgroundBreast cancer at bone metastatic sites: recent discoveries and treatment targets
Hussein, O., & Komarova, S. V. (2011) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-011-0117-3 · Cited by 42
Self-citationSundaresan, N., Boriani, S., & Okuno, S. H. (2009) · Spine · doi:10.1097/brs.0b013e3181bac476 · Cited by 42
“It has been suggested that RANKL can act as a tissue specific factor for migration of cancer cells, and RANKL is the prominent “soil” factor for bone-specific metastases.(152) In osteolytic metastases, bone destruction is mediated by osteoclasts, but the factors responsible for its activation vary according to tumor.”
BackgroundStress and catecholamines modulate the bone marrow microenvironment to promote tumorigenesis
Hanns, P., Paczulla, A., Medinger, M., Konantz, M., & Lengerke, C. (2019) · Cell Stress · doi:10.15698/cst2019.07.192 · Cited by 42
Rachner, T. D., Benad, P., Rauner, M., Goettsch, C., Singh, S. K., Schoppet, M., & Hofbauer, L. C. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22232 · Cited by 41
“Some tumors appear to cause an imbalance of the OPG/RANKL ratio, with a shift towards RANKL, which has been demonstrated to promote osteoclast activity and to enhance the development of osteolytic lesions, a characteristic feature of advanced breast cancer [Mundy, 1997].”
BackgroundInfluentialKagiya, T. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4091741 · Cited by 40
“In contrast, the RANK–RANKL interaction is inhibited by the decoy receptor osteoprotegerin (OPG), a soluble member of the TNF receptor superfamily expressed by stromal cells and osteoblasts [9,10] (Figure 1).”
BackgroundPrecision Oncology in Sarcomas: Divide and Conquer
Pestana, R. C., Groisberg, R., Roszik, J., & Subbiah, V. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00247 · Cited by 40
Shin, M., Matsuo, K., Tada, T., Fukushima, H., Furuta, H., Ozeki, S., Kadowaki, T., Yamamoto, K., Okamoto, M., & Jimi, E. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr198 · Cited by 40
Biology and clinical management of prostate cancer bone metastasis
Ye, X.-C., Choueiri, M., Tu, S.-M., & Lin, S.-H. (2007) · Frontiers in bioscience · doi:10.2741/2311 · Cited by 40
“activator of NF-κB ligand (RANKL), which stimulates cancer cell migration (59).”
BackgroundActin dynamics during tumor cell dissemination
(2021) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2020.09.004 · Cited by 39
Ouyang, J., Hu, S., Zhu, Q., Li, C., Kang, T., Xie, W., Wang, Y., Li, Y., Lu, Y., Qi, J., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06806-3 · Cited by 39
Thorny ground, rocky soil: Tissue-specific mechanisms of tumor dormancy and relapse
Lim, A. R., & Ghajar, C. M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.007 · Cited by 39
Clézardin, P. (2011) · Bulletin du Cancer · doi:10.1684/bdc.2011.1398 · Cited by 39
Kerr, B. A., Miocinovic, R., Smith, A. K., Klein, E. A., & Byzova, T. V. (2010) · Neoplasia · doi:10.1593/neo.10166 · Cited by 39
Metadata
- Authors
- Jones, D. H., Nakashima, T., Sanchez, O. H., Kozieradzki, I., Komarova, S. V., Sarosi, I., Morony, S., Rubin, E., Sarao, R., Hojilla, C. V., Komnenovic, V., Kong, Y.-Y., Schreiber, M., Dixon, S. J., Sims, S. M., Khokha, R., Wada, T., & Penninger, J. M.
- Affiliations
- Institute of Molecular Biotechnology (AT)
- University Health Network (CA)
- McGill University (CA)
- Amgen (United States) (US)
- University of Toronto (CA)
- Pohang University of Science and Technology (KR)
- Medical University of Vienna (AT)
- Western University (CA)
- Corresponding author
- Penninger, Josef M.
- ORCID
- Venue
- Nature
- Published
- 2006-03
- Volume
- 440
- Issue
- 7084
- Pages
- 692-696
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2051255001
- Cited by
- 796
- References
- 22
- Citations by year
- 2026: 10 · 2025: 21 · 2024: 24 · 2023: 32 · 2022: 33 · 2021: 43 · 2020: 43 · 2019: 39 · 2018: 28 · 2017: 43 · 2016: 36 · 2015: 42 · 2014: 45 · 2013: 47 · 2012: 68
- FWCI
- 18.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Scholarship@Western (Western University) (submittedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- European Commission
- Oesterreichische Nationalbank
- Canadian Institutes of Health Research
- National Cancer Institute
- Institute of Musculoskeletal Health and Arthritis
- Canadian Arthritis Network
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- RANKL, RANK, bone metastasis, tumor cell migration, osteoprotegerin, melanoma, breast cancer, tumor microenvironment, NF-κB signaling
- MeSH terms
- Animals, Bone Neoplasms, Breast Neoplasms, Carrier Proteins, Cell Differentiation, Cell Movement, Epithelial Cells, Female, Humans, Melanoma, Membrane Glycoproteins, Neoplasm Metastasis, Organ Specificity, Paralysis, Signal Transduction, Cell Death, Cell Line, Tumor, Cell Proliferation, Mice, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.